SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

Exclusion Criteria

• •1. Previously been treated with any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.)
• •2. Received any other anti-tumor therapy at the same time
• •3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer
• •4. Stage IV breast cancer
• •5. Not confirmed by histopathology
• •6. With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer
• •7. Participated in other drug clinical trials within 4 weeks before enrollment
• •8. Known allergic history of the drug components of this protocol
• •9. History of immunodeficiency
• •10. Clinically significant cardiovascular diseases
• •11. Known or suspected interstitial lung disease
• •12. Active hepatitis and liver cirrhosis
• •13. Known hereditary or acquired bleeding thrombotic tendency
• •14. History of neurological or psychiatric disorders